Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Axogen, Inc. (NASDAQ: AXGN) reported Q4 and full-year 2021 financial results, showing a 3% decline in Q4 revenue at $31.5 million compared to Q4 2020. Full-year revenue rose 13% to $127.4 million.
The adjusted net loss for Q4 stood at $3.3 million, unchanged from the previous year, while the gross margin was 82.8%. The company anticipates 2022 revenue between $135 million and $142 million, projecting growth of 10% to 15% over 2021.
Axogen, Inc. (NASDAQ: AXGN) will participate in two upcoming investor conferences in February 2022. CEO Karen Zaderej will engage in a fireside chat at the BTIG Virtual MedTech Conference on February 15 at 1:25 p.m. ET and at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 1:40 p.m. ET. Both discussions will be accessible via Axogen's Investors page, with a replay available post-event for 90 days. Axogen specializes in innovative solutions for peripheral nerve injuries, focusing on restoring nerve function and improving patient quality of life.
Axogen, Inc. (AXGN) will report its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market. An investment-community conference call will be held at 4:30 p.m. ET, accessible via phone or live webcast through their website. Axogen specializes in surgical solutions for peripheral nerve injuries, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Their portfolio aims to restore nerve function and quality of life for patients worldwide.
Axogen (NASDAQ: AXGN) reported expected fourth quarter revenue of approximately $31.5 million, down 3% from $32.5 million in Q4 2020. For the full year 2021, revenue is projected to be around $127.3 million, marking a 13% increase from $112.3 million in 2020. The decline in Q4 revenue is attributed to surgical volume fluctuations and COVID-19 impacts. The company expanded its sales force and core accounts, with 294 Core Accounts, a 9% increase year-over-year. Axogen anticipates releasing RECON study results in Q2 2022.
Axogen (AXGN) will feature its nerve repair platform at the combined 2022 meetings of the American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery from January 11-18 in Carlsbad, CA. An educational symposium on January 13 will discuss evidence-based nerve repair strategies. Key presentations include studies on nerve grafts and reconstruction techniques. CEO Karen Zaderej emphasized the growing interest in peripheral nerve repair and Axogen's commitment to patient outcomes through innovative solutions.
Axogen, Inc. (NASDAQ: AXGN) announces that patient Christopher Brown will feature in the 2022 Donate Life Rose Parade Float, honoring organ donor Paul Flanders. The event, aimed at raising awareness for organ and tissue donation, will take place on New Year’s Day in Pasadena, CA. Brown's recovery from chronic pain due to nerve damage after an amputation was made possible through nerve repair surgery using donated tissue. Axogen's CEO, Karen Zaderej, emphasized the importance of donation and the company's commitment to improving quality of life for nerve injury patients.
Axogen, Inc. (NASDAQ: AXGN) announced that CEO Karen Zaderej will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 10:00 a.m. ET. The presentation will be available via live webcast on Axogen's Investors page, with a recorded replay accessible for 90 days post-event. Axogen specializes in innovative surgical solutions for peripheral nerve injuries, offering products like Avance® Nerve Graft and Axoguard® devices that aid in nerve repair and regeneration.
Axogen, Inc. (NASDAQ: AXGN) announced that CEO Karen Zaderej will present at the Jefferies London Healthcare Conference on November 17, 2021, at 4:25 p.m. (11:25 a.m. ET). The presentation will be streamed live on the company's Investors page, with a replay available for 90 days. Axogen specializes in innovative surgical solutions for peripheral nerve injuries, aiming to restore nerve function and quality of life for patients. Their product portfolio includes Avance® Nerve Graft and Axoguard series, designed to effectively repair peripheral nerves.
Axogen, Inc. (NASDAQ: AXGN) reported Q3 2021 net revenue of $31.2 million, a 7% decline from $33.4 million in Q3 2020. The net loss increased to $7.1 million, or $0.17 per share, compared to a net loss of $1.5 million, or $0.04 per share, in the prior year. Despite lower procedure volumes due to COVID-19 challenges, gross margin improved to 83.2%. The company revised its 2021 revenue guidance to between $127 million and $129 million, down from the previous estimate of $134.5 million to $137.5 million.
Axogen (NASDAQ: AXGN) will report its third quarter 2021 financial results on November 3, 2021, after market close. Following this, management will host a conference call at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen to the webcast on the company's website. Axogen specializes in surgical solutions for peripheral nerve damage, offering products like Avance® Nerve Graft and Axoguard Nerve Protector® to aid in nerve repair and regeneration, thus improving patients' quality of life.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
What is Axogen, Inc. focused on?
What are some key products offered by Axogen?
In which markets are Axogen's products available?
What recent product did Axogen launch?
What is the Avance® Nerve Graft?
How did Axogen perform financially in Q4 2023?
What does the Axoguard® Nerve Cap do?
What is the function of the Axotouch® Two-Point Discriminator?
Who is the current CEO of Axogen?
Where can I find more information about Axogen?
